Google Cloud unveils AI-led solutions to speed up drug discovery
hapabapa
Google Cloud on Tuesday launched two new AI-powered life sciences solutions aimed at biotech and pharmaceutical companies to help them accelerate drug discovery and advance precision medicine.
The tools known as Target and Lead Identification Suite and Multiomics Suite will be available globally, Google Cloud, a unit of search giant Google owned by Alphabet (NASDAQ:GOOG) (NASDAQ:GOOGL), said.
Target and Lead Identification Suite is designed to better understand the function of amino acids and forecast the structure of proteins.
It can help companies to accelerate the development of therapeutics such as antibodies. Google Cloud cited Pfizer (NYSE:PFE) and Cerevel Therapeutics (NASDAQ:CERE) as some of the early adopters of the technology.
Multiomics Suite, more focused on the analysis and interpretation of genomic data, can support the advancement of precision medicines, and genetic engineering company Colossal Biosciences is already using the tool.
"These new solutions launching today can transform life sciences organizations by accelerating drug discovery and bringing therapeutics to market faster," said Shweta Maniar, Google Cloud's global director for Life Sciences Strategy and Solutions.
"When patients are waiting for that life-saving treatment in cancer care or that quality-of-life medicine for migraine headaches, this faster time-to-market can have an incredibly positive impact on lives," she added.
More on Google Cloud

Google opening second cloud region in Italy
Google Earnings Highlights: Cloud Appears Set For Success